Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback